387 related articles for article (PubMed ID: 8455937)
21. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
[TBL] [Abstract][Full Text] [Related]
22. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
Beaulieu ME; McDuff FO; Frappier V; Montagne M; Naud JF; Lavigne P
J Mol Recognit; 2012 Jul; 25(7):414-26. PubMed ID: 22733550
[TBL] [Abstract][Full Text] [Related]
23. Taking myc to the max.
Turner R
Nat Struct Biol; 2003 Mar; 10(3):157. PubMed ID: 12605219
[No Abstract] [Full Text] [Related]
24. c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs.
Tobias KE; Shor J; Kahana C
Oncogene; 1995 Nov; 11(9):1721-7. PubMed ID: 7478599
[TBL] [Abstract][Full Text] [Related]
25. The mechanism of discrimination between cognate and non-specific DNA by dimeric b/HLH/LZ transcription factors.
Sauvé S; Naud JF; Lavigne P
J Mol Biol; 2007 Jan; 365(4):1163-75. PubMed ID: 17109882
[TBL] [Abstract][Full Text] [Related]
26. Analysis of c-Myc and Max binding to the c-myc promoter: evidence that autosuppression occurs via an indirect mechanism.
Buckle RS; Méchali M
Oncogene; 1995 Mar; 10(6):1249-55. PubMed ID: 7700652
[TBL] [Abstract][Full Text] [Related]
27. Thermodynamics of b-HLH-LZ protein binding to DNA: the energetic importance of protein-DNA contacts in site-specific E-box recognition by the complete gene product of the Max p21 transcription factor.
Meier-Andrejszki L; Bjelić S; Naud JF; Lavigne P; Jelesarov I
Biochemistry; 2007 Oct; 46(43):12427-40. PubMed ID: 17915948
[TBL] [Abstract][Full Text] [Related]
28. Max and c-Myc/Max DNA-binding activities in cell extracts.
Littlewood TD; Amati B; Land H; Evan GI
Oncogene; 1992 Sep; 7(9):1783-92. PubMed ID: 1501888
[TBL] [Abstract][Full Text] [Related]
29. Protein complexes bearing myc-like antigenicity recognize two distinct DNA sequences.
Negishi Y; Iguchi-Ariga SM; Ariga H
Oncogene; 1992 Mar; 7(3):543-8. PubMed ID: 1549367
[TBL] [Abstract][Full Text] [Related]
30. C-myc and the yeast transcription factor PHO4 share a common CACGTG-binding motif.
Fisher F; Jayaraman PS; Goding CR
Oncogene; 1991 Jul; 6(7):1099-104. PubMed ID: 1861859
[TBL] [Abstract][Full Text] [Related]
31. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
[TBL] [Abstract][Full Text] [Related]
32. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
[TBL] [Abstract][Full Text] [Related]
34. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
35. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis.
McDuff FO; Naud JF; Montagne M; Sauvé S; Lavigne P
J Mol Recognit; 2009; 22(4):261-9. PubMed ID: 19189276
[TBL] [Abstract][Full Text] [Related]
36. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc.
FitzGerald MJ; Arsura M; Bellas RE; Yang W; Wu M; Chin L; Mann KK; DePinho RA; Sonenshein GE
Oncogene; 1999 Apr; 18(15):2489-98. PubMed ID: 10229200
[TBL] [Abstract][Full Text] [Related]
38. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
[TBL] [Abstract][Full Text] [Related]
39. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
[TBL] [Abstract][Full Text] [Related]
40. Elucidation of the structural determinants responsible for the specific formation of heterodimeric Mxd1/Max b-HLH-LZ and its binding to E-box sequences.
Montagne M; Naud JF; Lavigne P
J Mol Biol; 2008 Feb; 376(1):141-52. PubMed ID: 18155722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
